Your session is about to expire
← Back to Search
SQ tree SLIT-tablet for Allergy (TreeTop Trial)
Phase 3
Waitlist Available
Led By Monika Gappa, Prof. Dr. Med.
Research Sponsored by ALK-Abelló A/S
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
TreeTop Trial Summary
This trial is testing whether the medication is effective and safe to treat birch/tree pollen allergy in children and adolescents.
TreeTop Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Pharmaceutical Preparations
Secondary outcome measures
Average daily medication score during the birch pollen season
Average daily medication score during the tree pollen season
Average daily symptom score during the birch pollen season
+2 moreTreeTop Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Intervention/treatmentExperimental Treatment1 Intervention
Sublingual allergy immunotherapy tablet, for daily administration SQ tree SLIT-tablet
Group II: PlaceboPlacebo Group1 Intervention
Gelatine (fish source), mannitol and sodium hydroxide
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
SQ tree SLIT-tablet
2015
Completed Phase 3
~1140
Find a Location
Who is running the clinical trial?
ALK-Abelló A/SLead Sponsor
76 Previous Clinical Trials
327,390 Total Patients Enrolled
ParexelIndustry Sponsor
305 Previous Clinical Trials
100,199 Total Patients Enrolled
Monika Gappa, Prof. Dr. Med.Principal InvestigatorEvangelisches Krankenhaus Düsseldorf
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger